Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Eisai Makes World’s 2nd Launch of Lenvima for Thyroid Cancer in Japan following US
May 21, 2015
- Gilead to Launch Sovaldi on May 25, with Proper Use Promotion by 150 Sales Reps
May 21, 2015
- Top 4 Drug Wholesalers Report 0.82% Operating Profit Rate in FY2014
May 20, 2015
- R-Tech Ueno Ties Up with Hokkaido University to Develop VAP-1 Inhibitor
May 20, 2015
- Quintiles Acquires Clio Science to Enhance Oncology, CNS Expertise
May 20, 2015
- Biogen Japan Sets to Quadruple Sales in 2 Years: New Chief
May 19, 2015
- Meiji Holdings Aims at Sales of 180 Billion Yen and 30% Overseas Sales Ratio in Pharma Business by FY2017
May 19, 2015
- Japan’s Biosimilar Market to Rise to 31.4 Billion Yen in 2017: Fuji Keizai
May 19, 2015
- Sanofi Launches Menactra, Preventive Vaccine for Invasive Meningococcal Diseases
May 19, 2015
- Takeda Sees Lower Japan Sales for FY2015 on Generic Pressure
May 18, 2015
- Takeda Incurs Huge Red Ink on Actos Settlement, CEO Says Financial Uncertainty Lessened
May 18, 2015
- Daiichi Sankyo Exits Global Hybrid Biz Model, Now Focuses on Innovation
May 18, 2015
- Takeda Discontinues Development of Bipolar Disorder Treatment TAK-375SL
May 18, 2015
- Masanobu Kambara Becomes UCB Japan President
May 18, 2015
- Mochida Terminates License Deal with US Merck for Type 2 Diabetes Treatment
May 18, 2015
- MTPC Files Remicade for Kawasaki Disease
May 18, 2015
- Daiichi Sankyo Profit Quintuples on Gains from Ranbaxy-Sun Merger
May 15, 2015
- Eisai Earnings Pummeled by Generic Erosions in Japan, US
May 15, 2015
- Mitsubishi Chemical Group to Strengthen Presence in Field of Regenerative Medicine by Acquiring Clio Inc.
May 15, 2015
- Vital KSK Holdings Names Taisuke Murai as President
May 15, 2015
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…